Nuvascular Harbor Occlusion Device Pilot Study (NCT07117526) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Nuvascular Harbor Occlusion Device Pilot Study
Bulgaria10 participantsStarted 2025-10-01
Plain-language summary
The purpose of this study is to evaluate the safety and effectiveness of the HARBOR Occlusion Device for treating brain aneurysms. The HARBOR Device is investigational (experimental), meaning the Regulatory Authorities have not approved it for commercial use. The data collected in this research study will be used to analyze whether the HARBOR Device is safe and effective in treating brain aneurysms.
Who can participate
Age range18 Years – 79 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patient must be 18-79 years of age at the time of screening.
✓. Patient must have a single unruptured IA requiring treatment. If the subject has an additional IA requiring treatment, the additional IA must not require treatment within 60 days of the index procedure.
✓. The index IA to be treated must have the following characteristics:
✓. Saccular in shape
✓. Diameter 2.5 mm to 12.0 mm
✓. IA is appropriate for treatment with the HARBOR Occlusion Device per device Instructions for Use
✓. Patient has an IA that is appropriate for treatment with HARBOR Occlusion Device without the use of additional implanted devices
✓. Patient must be able to comply with all aspects of the screening, evaluation, treatment, and the post-procedure follow-up schedule. Patient must sign and date an IRB/EC-approved written informed consent prior to initiation of any study procedures.
Exclusion criteria
✕. Patient has a ruptured IA, defined as a patient with computed tomography (CT), magnetic resonance imaging (MRI), or lumbar puncture (LP) evidence of subarachnoid hemorrhage attributed to the index aneurysm within the last 180 days.
✕. Patient has an IA with characteristics unsuitable for endovascular treatment.
✕. Microcatheter could not reach patient's index aneurysm to allow necessary access to treat with study device.
What they're measuring
1
Participants meeting the primary safety and effectiveness endpoints
✕. Patient has vessel characteristics, tortuosity or morphology which could preclude safe access and support during treatment with study device;
✕. Patient has vascular disease or other vascular anomaly so as to preclude the necessary access to the aneurysm for use of the study device.
✕. Patient has clinical, angiographic or CT evidence of vasospasm, vasculitis, or intracranial tumor (except small meningioma) or any other intracranial vascular malformations on presentation.
✕. Patient has conditions placing them at high risk for ischemic stroke or has exhibited ischemic symptoms such as transient ischemic attacks, minor strokes, or stroke-in-evolution within the prior 60 days.
✕. Patient has any circulatory, neurovascular, cardiovascular, or neurologic conditions that have resulted in unstable neurological symptoms.